FASEB SRC on The Growth Hormone/Prolactin Family in Biology and Disease
FASEB SRC on The Growth Hormone/Prolactin Family in Biology and Disease
批准号:
8318368
负责人:
CHRISTIN CARTER-SU
金额:
$0.8万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2017-05-31
关键词:
AffectAgingAnimal ModelAreaBehaviorBeta CellBiologyBrainClinicalCommunitiesComplexCytokine ReceptorsDataDetectionDevelopmentDiabetes MellitusDiseaseDrug Delivery SystemsEndocrinologyEnsureFamilyFunctional disorderFundingGrowthHealthHormonesHumanImmune responseIndustryInvestigationLactationLifeMalignant NeoplasmsMammary glandMental HealthMetabolismModelingMolecularMuscleNegative FindingObesityOrganPancreasParticipantPharmaceutical PreparationsPharmacotherapyPhysiologicalPlacental LactogenProcessProlactinProstateProtein FamilyProteinsPublicationsRegulationResearchResearch PersonnelSignal TransductionSomatotropinSomavertStructureTissuesabstractingadipocyte differentiationbaseblood glucose regulationbonecytokinedrug developmentimprovedmeetingsmemberneurogenesisnovelnovel strategiesnovel therapeuticsposterspreclinical studypreventprofessorstem cell biologysymposium
中文摘要
描述(由申请人提供):“生长激素(GH)和催乳素(PRL)家族”定义了一个蛋白质家族,该蛋白质家族包括几个成员,包括GH、PRL、胎盘催乳素(PL)和称为血管生成素的各种蛋白水解片段。这些蛋白质处于人类病理生理学两个主要领域的交叉点:细胞因子受体(它们与细胞因子受体共享多种分子机制)和(神经)内分泌学(在调节、分泌、功能和病理生理学水平上与其他激素的多种联系)。在这两个领域,GH和PRL激素率先发现了范式,从作用机制(例如,1992年首次发现细胞因子和受体复合物的结构)到药物开发(Somavert,2003年推出的第一种基于细胞因子核心的拮抗剂)。现在很清楚,PRL和GH激素调节代谢(例如,β细胞量、脂肪细胞分化、肌肉、葡萄糖稳态等),干细胞生物学,行为(例如,这些新的功能对科学界来说是非常令人兴奋的,包括该领域的基础,翻译,临床和工业演员。进一步的转化研究是必要的,以了解这些新功能的潜在机制,以评估其实际的临床影响,发现新的治疗适应症,开发靶向药物治疗和兴奋剂检测的新策略。因此,迫切需要通过组织一次定期和长期的会议,集中讨论这些问题,从而使参与这些研究领域的越来越多的人聚集在一起。为此,申请人已经建立了一个新的FASEB SRC,标题为“生物学和疾病中的生长激素和催乳素家族”。会议将涵盖多种领域,如信号传导,开发新的动物模型以识别GH和PRL在健康和疾病中的新生理功能,GH和PRL激素调节的新功能/组织,GH和PRL作用的生物学分析以及新药靶点和临床前研究。最后,申请人将通过从将提交的摘要中选择简短的演讲(提供符合我们的质量标准的演讲),确保涵盖最新的新发现和目前未包括在完整演讲中的相关主题。将作出重大努力吸引年轻的调查人员(提供资金、举办简短的讲座、张贴海报)。
公共卫生相关性:生长激素和催乳激素家族不仅调节身体生长和泌乳。它们还涉及促进或预防肥胖、糖尿病、衰老、心理健康和癌症等重大健康问题。这个新的FASEB夏季研究会议的主要目标是汇集关注这些激素的社区(学术界,临床医生,工业界),以激发讨论,分享未发表的数据,提高对相关疾病过程的理解并加速新药的发现。
英文摘要
DESCRIPTION (provided by applicant): The "Growth hormone (GH) and prolactin (PRL) family" defines a protein family that includes several members, including GH, PRL, placental lactogens (PLs) and various proteolytic fragments called vasoinhibins. These proteins are at the crossroads of two major fields in human pathophysiology: cytokine receptors (with whom they share multiple molecular mechanisms), and (neuro) endocrinology (multiple connections with other hormones at the regulation, secretion, functional and pathophysiology levels). In both areas, GH and PRL hormones have pioneered the discovery of paradigms, ranging from mechanisms of action (e.g., first known structure of cytokine and receptor complex in 1992) to drug development (Somavert, the first cytokine core-based antagonist launched in 2003). It is now clear that PRL and GH hormones regulate metabolism (e.g., beta cell mass, adipocyte differentiation, muscle, glucose homeostasis, etc), stem cell biology, behavior (e.g., neurogenesis), cancer (several organs), immune responses, etc. These novel functions are very exciting to the scientific community, including basic, translational, clinical and industrial actor in the field. Further translational investigations are necessary to understand the underlying mechanisms of these novel functions to evaluate their actual clinical impact discover new therapeutic indications, develop targeted drug therapy, and novel strategies of doping detection. There is therefore a critical need to gather the broadening community involved in these fields of research by organizing a regular and long-live meeting focused on these issues. To that end, the applicants have established a novel FASEB SRC entitled "The Growth Hormone and Prolactin Family in Biology and Disease". The conference will cover such diverse areas as signaling, development of novel animal models for identifying new physiological functions for GH and PRL in health and disease, new functions/tissues regulated by GH and PRL hormones, biomics profiling of GH and PRL actions and new drug targets and pre-clinical studies. Finally, the applicants will ensure coverage of the latest new findings and relevant topics not currently included as full talks by selecting short talks from abstracts that will be submitted (providing thy match our quality criteria). Major efforts to attract young investigators will be made (funding, short talks, posters).
PUBLIC HEALTH RELEVANCE: The growth hormone and prolactin family of hormones not only regulate body growth and lactation. They have also been implicated in contributing to or preventing such major health problems as obesity, diabetes, aging, mental health and cancer. The main objective of this novel FASEB summer research conference is to bring together the community (academic, clinicians, industry) focused on these hormones in order to stimulate discussion, share unpublished data, improve the understanding of related disease processes and accelerate the discovery of new drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cellular and Molecular Mechanisms of SH2B1 Mutations That Cause Profound Childhood Obesity
-
批准号:9456743
-
项目类别:
-
资助金额:$45.42万
-
财政年份:2016
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Cellular and Molecular Mechanisms of SH2B1 Mutations That Cause Profound Childhood Obesity
-
批准号:9923644
-
项目类别:
-
资助金额:$45.42万
-
财政年份:2016
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Cellular and Molecular Mechanisms of SH2B1 Mutations That Cause Profound Childhood Obesity
-
批准号:9176711
-
项目类别:
-
资助金额:$45.42万
-
财政年份:2016
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Cellular and Molecular Mechanisms of SH2B1 Mutations That Cause Profound Childhood Obesity
-
批准号:9307814
-
项目类别:
-
资助金额:$45.42万
-
财政年份:2016
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
FASEB SRC on The Growth Hormone/Prolactin Family in Biology and Disease
-
批准号:8502486
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
FASEB SRC on The Growth Hormone/Prolactin Family in Biology and Disease
-
批准号:8685256
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2012
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Receptors and Actions
-
批准号:7992537
-
项目类别:
-
资助金额:$6.65万
-
财政年份:2009
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2-B
-
批准号:7072367
-
项目类别:
-
资助金额:$36.11万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2B1
-
批准号:8324747
-
项目类别:
-
资助金额:$45.24万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Cellular mechanism of action of SH2B1 isoforms implicated in human obesity
-
批准号:9902396
-
项目类别:
-
资助金额:$46.47万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
GROWTH HORMONE REGULATION OF SH2B
-
批准号:2856841
-
项目类别:
-
资助金额:$31.83万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
GROWTH HORMONE REGULATION OF SH2B
-
批准号:6381186
-
项目类别:
-
资助金额:$33.86万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2-B
-
批准号:6826387
-
项目类别:
-
资助金额:$36.73万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2B1
-
批准号:8719086
-
项目类别:
-
资助金额:$39.14万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2-B
-
批准号:7235318
-
项目类别:
-
资助金额:$34.83万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
GROWTH HORMONE REGULATION OF SH2B
-
批准号:6635105
-
项目类别:
-
资助金额:$35.41万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2-B
-
批准号:6917824
-
项目类别:
-
资助金额:$36.98万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
GROWTH HORMONE REGULATION OF SH2B
-
批准号:6517490
-
项目类别:
-
资助金额:$34.38万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2-B
-
批准号:7426865
-
项目类别:
-
资助金额:$34.13万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
Growth Hormone Regulation of SH2B1
-
批准号:8408883
-
项目类别:
-
资助金额:$4.06万
-
财政年份:1999
-
负责人:CHRISTIN CARTER-SU
-
依托单位:
海外基金